Detalhe da pesquisa
1.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med
; 381(16): 1535-1546, 2019 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562797
2.
PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma.
J Cutan Med Surg
; 26(3): 243-248, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34866423
3.
A Clinicoepidemiological Study of Melanoma in Young Patients (20 Years of Age or Less) in Alberta, Canada, From 1992 to 2011.
J Cutan Med Surg
; 25(2): 133-141, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33095029
4.
Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Oncologist
; 25(5): 438-446, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32048768
5.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med
; 377(19): 1824-1835, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28891423
6.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med
; 377(14): 1345-1356, 2017 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28889792
7.
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
N Engl J Med
; 375(19): 1845-1855, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27717298
8.
Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials.
Support Care Cancer
; 27(4): 1551-1561, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30547303
9.
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Lancet Oncol
; 19(11): 1480-1492, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30361170
10.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med
; 373(1): 23-34, 2015 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26027431
11.
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 18(3): 393-403, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28162999
12.
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 18(5): 611-622, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28359784
13.
Sun-Smart Practices Amongst School Students (Grades 5, 7, and 9) in Alberta, Canada.
J Cutan Med Surg
; 21(2): 137-144, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28300452
14.
Immune checkpoint inhibitor-induced granulomatosis with polyangiitis.
Rheumatology (Oxford)
; 60(6): e190-e191, 2021 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33367837
15.
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 16(5): 522-30, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25840693
16.
Can radiation restore immunotherapy response in metastatic melanoma refractory to checkpoint inhibitors: An institutional experience in salvaging immunotherapy resistant disease.
Radiother Oncol
; 185: 109712, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37178931
17.
Skeletal muscle is prognostic in resected stage III malignant melanoma.
Clin Nutr
; 41(5): 1066-1072, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35397311
18.
Patterns and predictors of relapse in Merkel cell carcinoma: Results from a population-based study.
Radiother Oncol
; 166: 110-117, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838888
19.
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
J Clin Oncol
; 40(2): 127-137, 2022 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34818112
20.
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
Lancet Oncol
; 11(2): 155-64, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20004617